Product Description
Mechanisms of Action: TK Inhibitor, ERBB2 Inhibitor, EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aslan
Company Location: SINGAPORE U0 239920
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Biliary Tract Cancer|Gallbladder Cancer|Papillary Carcinoma|Cholangiocarcinoma|Gastrointestinal Cancer
Phase 2: Breast Cancer|Biliary Tract Cancer|Gastrointestinal Cancer|Cholangiocarcinoma|Pancreatic Cancer|Hepatocellular Carcinoma
Phase 1: Biliary Tract Cancer|Oncology Solid Tumor Unspecified|Papillary Carcinoma|Gallbladder Cancer|Cholangiocarcinoma|Breast Cancer|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Weight Gain|Obesity |
2020-07-31 |
|||
| ASLAN001-002SG | P1 |
Unknown status |
Oncology Solid Tumor Unspecified |
2021-06-01 |
2023-04-15 |
Primary Endpoints |
|
| ASLAN001-010 | P1 |
Completed |
Biliary Tract Cancer |
2017-12-07 |
2025-08-27 |
Primary Endpoints|Treatments |
|
| ASLAN001-018 | P1 |
Completed |
Healthy Volunteers |
2017-12-06 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| ASLAN001-002 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-06-12 |
2023-04-15 |
||
| ARRAY-543-103 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-10-01 |
2020-10-07 |
Primary Endpoints|Treatments |
|
| ARRAY-543-204 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-04-01 |
2020-10-07 |
||
| ARRAY-543-104 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-07-01 |
2020-10-07 |
Primary Endpoints|Treatments |
|
| ARRY-0501 | P1 |
Completed |
Breast Cancer |
2009-06-01 |
2020-10-16 |
||
| JapicCTI-173497 | P1 |
Completed |
Biliary Tract Cancer|Papillary Carcinoma|Gallbladder Cancer|Cholangiocarcinoma |
None |
|||
| ASLAN001-007 | P2 |
Terminated |
Biliary Tract Cancer |
2020-06-16 |
2023-04-15 |
||
| ASLAN001-016 | P2 |
Withdrawn |
Biliary Tract Cancer |
2020-03-01 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| ASLAN001-006 | P2 |
Terminated |
Breast Cancer |
2020-01-14 |
2025-09-11 |
Primary Endpoints|Treatments |
|
| ASLAN001-008 | P2 |
Completed |
Biliary Tract Cancer |
2019-07-05 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| HC01/12/16 | P2 |
Unknown status |
Hepatocellular Carcinoma |
2019-05-05 |
2021-05-07 |
Primary Endpoints|Treatments|Trial Status |
|
| NCT02396108 | P2 |
Unknown status |
Breast Cancer |
2018-03-01 |
2019-03-20 |
Treatments |
|
| ASLAN001-005 | P2 |
Completed |
Cholangiocarcinoma |
2017-07-07 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| ASLAN001-003 | P2 |
Completed |
Breast Cancer |
2016-05-19 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| ASLAN001-001 | P2 |
Completed |
Gastrointestinal Cancer |
2013-03-01 |
2023-04-15 |
Primary Endpoints|Treatments |
|
| ARRAY-543-206 | P2 |
Completed |
Pancreatic Cancer |
2011-02-01 |
2019-03-18 |
||
| JapicCTI-183951 | P3 |
Unknown |
Cholangiocarcinoma|Biliary Tract Cancer|Papillary Carcinoma|Gallbladder Cancer |
2019-12-31 |
|||
| TreeTopp | P3 |
Completed |
Biliary Tract Cancer |
2019-11-12 |
28% |
2023-04-15 |
Primary Endpoints|Treatments |
| TreeTopp | P3 |
Terminated |
Biliary Tract Cancer |
2019-11-12 |
2022-03-13 |
Treatments |
|
| 2017-001833-15 | P3 |
Terminated |
Gastrointestinal Cancer |
2019-01-31 |
2025-06-28 |
Treatments |
|
| First Line | P3 |
Completed |
Gastrointestinal Cancer |
2018-12-20 |
2023-04-15 |
Primary Endpoints|Treatments |